Lipids & metabolic liver disease
Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with cardiovascular-kidney-metabolic (CKM) stages 0–2: Mediating roles of inflammation and insulin resistance
Main finding · CVD mortality, CKM stages 0-2Result — go to the resultHazard ratio 4.03 95 % CI 1.55–10.48Authors' conclusion
In early CKM syndrome, MASLD was associated with higher CVD mortality risk. Insulin resistance and inflammation may partly explain this association.
Study context
- Population
- US adults with CKM staging, NHANES 2009–2018; key analysis in CKM stages 0–28,340 at stages 0–2
- Participants
- 10,061 adults
- Exposure
- MASLD vs no MASLD
- Outcome
- CVD mortality
Methodological detailsNHANES 2009-2018, multivariable Cox regression, mediation analysis
- NHANES 2009-2018
- Multivariable Cox regression
- Mediation analysis
Main finding
CVD mortality, CKM stages 0-2
Hazard ratio
4.03
95 % CI 1.55–10.48
MASLDvs Without MASLD
HR 4.03 (95 % CI 1.55–10.48)
As reported in the abstract
- United States Fatty Liver Index (USFLI) scores linearly correlated with cardiovascular disease (CVD) mortality risk
- P < 0.001
Observational data: associations, not effects.
Further findings
MASLD prevalence by CKM stage
- MASLD prevalence rose with CKM stage progression
Mediation
- Insulin resistance and inflammation partially mediated the association
Original publication
Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0–2: Mediating roles of inflammation and insulin resistance. Diabetes Res Clin Pract. Published 11 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →